Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs

Blood

Volumn 102, Issue 13, 2003, Pages 4393-4398

  Russell, Karen E ^b   Olsen, Eva H N ^b   Raymer, Robin A ^b   Merricks, Elizabeth P ^b   Bellinger, Dwight A ^b   Read, Marjorie S ^b   Rup, Bonita J ^b   Keith Jr , James C ^b   McCarthy, Kyle P ^b   Schaub, Robert G ^b   Nichols, Trimothy C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 9;

ANIMAL MODEL; ARTICLE; BLEEDING; DOG; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOPHILIA; HEMOPHILIA B; NEWBORN; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 10744223774     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-05-1498     Document Type: Article

References (30)

1. High KA, Roberts HR. Factor IX. In: High KA, Roberts HR, eds. Molecular Basis of Thrombosis and Hemostasis. New York: Marcel Dekker, Inc; 1995:215-238.
2. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992;232:25-32.
3. Liesner RJ, Khair K, Hann IM. The impact of prophlyactic treatment on children with severe haemophilia. Br J Haematol. 1996;92:973-978.
4. Smith PS, Teutsch SM, Shaffer PA, Rolka H, Evatt B. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. J Pediatr. 1996;129:424-431.
5. Bohn RL, Avorn J, Glynn RJ, Choodnovskiy I, Haschemeyer R, Aledort LM. Prophylactic use of factor VIII: an economic evaluation. Thromb Haemost. 1998;79:932-937.
6. Bjorkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia. 2003;9(Suppl 1):101-110.
7. Russell KE, Read MS, Bellinger DA, et al. Intratracheal administration of recombinant human factor IX (BeneFix) achieves therapeutic levels in hemophilia B dogs. Thromb Haemost. 2001;85:445-449.
8. McCarthy KP, Timony GA, Ferranti TJ, et al. Subcutaneous bioavailability of recombinant factor IX (BeneFix™) in healthy beagle dogs and cynomolgus monkeys [abstract]. Blood. 1996;88:68b.
9. McCarthy K, Stewart P, Sigman J, et al. Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys. Thromb Haemost. 2002;87:824-830.
10. Brinkhous KM, Sigman JL, Read MS, et al. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B. Blood. 1996;88:2603-2610.
11. Herzog RW, Arruda VR, Fischer TH, Read MS, Nichols TC, High KA. Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill colony. Thromb Haemost. 2000;84:352-354.
12. Kay MA, Rothenberg S, Landen CN, et al. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science. 1993;262:117-119.
13. Evans JP, Brinkhous KM, Brayer GD, Reisner HM, High KA. Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci U S A. 1989;86:10095-10099.
14. Harrison S, Clancy B, Brodeur S, et al. Development of a serum-free process for recombinant factor IX expression in Chinese hamster ovary cells [abstract]. Thromb Haemost. 1995;73:1222.
15. Rodriques H, Giles K, Sefton L, Griffon V, Duxbury M, Letwin B. Analytical characterization of recombinant human factor IX: pharmacokinetic studies in the rat and the dog [abstract]. Thromb Haemost. 1995;73:1206.
16. Keith JC Jr, Ferranti TJ, Misra B, et al. Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dog. Thromb Haemost. 1995;73:101-105.
17. Barrow EM, Bullock WR, Graham JB. A study of the carrier state for plasma thromboplastin component (PTC, Christmas factor) deficiency, utilizing a new assay procedure. J Lab Clin Med. 1959;55:936-945.
18. Kasper CK, Aledort L, Aronson D, et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diathes Haemorrh. 1975;34:869-872.
19. Brinkhous KM, Graham JB. Hemophilia in the female dog. Science. 1950;111:723-724.
20. Ljung R, Petrini P, Tengborn L, Sjorin E. Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity. Br J Haematol. 2001;113:81-86.
21. Dimichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia. 2002;8:280-287.
22. Knobel KE, Sjorin E, Tengborn LI, Petrini P, Liung RC. Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey. Acta Paediatr. 2002;91:910-914.
23. Berrettini M, Iorio P, Nenci GG, Arcieri P, Mariani G. Subcutaneous factor IX administration to patients with hemophilia B. Am J Hematol. 1994;47:61-62.
24. Gerrard AJ, Austen DE, Brownlee GG. Subcutaneous injection of factor IX for the treatment of haemophilia B. Br J Haematol. 1992;81:610-613.
25. Liles D, Landen CN, Monroe DM, et al. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B. Thromb Haemost. 1997;77:944-948.
26. Cheung WF, van den Born J, Kuhn K, Kjellen L, Hudson BG, Stafford DW. Identification of the endothelial cell binding site for factor IX. Proc Natl Acad Sci U S A. 1996;93:11068-11073.
27. Heimark RL, Schwartz SM. Binding of coagulation factors IX and X to the endothelial cell surface. Biochem Biophys Res Commun. 1983;111:723-731.
28. Stern DM, Knitter G, Kisiel W, Nawroth PP. In vivo evidence of intravascular binding sites for coagulation factor IX. Br J Haematol. 1987;66:227-232.
29. Wolberg AS, Stafford DW, Erie DA. Human factor IX binds to specific sites on the collagenous domain of collagen IV. J Biol Chem. 1997;272:16717-16720.
30. Gui T, Lin HF, Jin DY, et al. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood. 2002;100:153-158.